RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
1. RAPT Therapeutics, Inc., a clinical-stage immunology-based therapeutics company, has appointed Michael Listgarten as General Counsel.
2. Brian Wong, President and CEO of RAPT, welcomed Michael, emphasizing his deep legal expertise and leadership experience from various biopharmaceutical companies.
3. Michael Listgarten has over 25 years of experience in law, primarily assisting biopharmaceutical companies transition from late-stage clinical development to commercial entities.
4. He previously served as Vice President of Healthcare Law & Chief Compliance Officer at Adamas Pharmaceuticals, where he oversaw legal support and ensured compliance.
5. Before Adamas, Listgarten served as Vice President of Healthcare Law at Principia Biopharma and spent 16 years at Genentech, Inc. leading a large team of attorneys.
6. Listgarten holds a J.D. and Masters of International Affairs from Columbia University, and a B.A. in Political Science from the University of Pennsylvania.
7. On his appointment, Listgarten expressed excitement about joining RAPT and contributing to the company's growth and the advancement of its product pipeline.
8. RAPT Therapeutics is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.
9. The company has developed two unique drug candidates, RPT193 and FLX475, targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively.
10. RAPT Therapeutics stated that the company is also pursuing a range of targets that are in the discovery stage of development.